Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70–80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.

Market Dynamics:

Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.

Key Features of the Study:

- This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global primary sclerosing cholangitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market

Detailed Segmentation-

• By Drug Class
  
  • Ursodeoxycholic acid (UDCA)
  • Corticosteroids 
  • Azathioprine 
  • Mercaptopurine 
  • Budesonide
  • Obeticholic acid
  • Monoclonal antibody
  • Others
• By Route of Administration
  
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region           
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG